Cooper Companies, Inc. (COO) · Sep 9, 2026 · Earnings

CooperCompanies beats EPS but misses revenue; keeps CooperSurgical, expands buyback

In line — Non-GAAP EPS $1.15 vs ~$1.12 consensus; revenue $1.066B vs ~$1.10B consensus

CooperCompanies topped EPS expectations but posted flat organic growth, warned on Q4 inventory, and ended the sale review without selling CooperSurgical.

The quarter was mixed against expectations, not a clean beat. Non-GAAP EPS of $1.15 exceeded the published consensus of roughly $1.12, but revenue of $1.066 billion fell short of expectations near $1.10 billion.

MetricQ3 2026Q3 2025 / expectation
Revenue$1,066.2M (Income Statement)$1,060.3M prior year; ~$1.10B consensus
Non-GAAP diluted EPS$1.15 (GAAP to non-GAAP reconciliation)$1.10 prior year; ~$1.12 consensus
Non-GAAP operating margin26% (GAAP to non-GAAP reconciliation)26% prior year
Organic revenue growth1% total; 0% CooperVision; 3% CooperSurgical (Segment results)—
Share repurchases$339.1M in Q3 (Share repurchase disclosure)Authorization expanded to $3.0B

The EPS beat was helped by cost control and a tax release, not stronger demand. Non-GAAP operating margin held at 26%, while GAAP EPS benefited heavily from the reversal of a $307.2 million tax reserve after the U.K. examination. The underlying revenue picture was much less impressive: total organic growth was only 1%, CooperVision was flat, and management said U.S. channel inventory reductions will continue to weigh on Q4. 〔0〕

The strategic review removes a potential breakup catalyst rather than creating one. The board evaluated selling CooperSurgical but concluded that offers were not attractive enough, so the business remains part of the company. 〔1〕 That outcome is partly known because the review and possible sale had already been disclosed; the new information is that no transaction cleared the board's valuation threshold.

Capital allocation is the clearest incremental positive. CooperCompanies expanded its repurchase authorization from $2 billion to $3 billion after buying back $339.1 million of shares during the quarter. This provides a tangible support to per-share results, but it does not offset the weaker demand signal from flat CooperVision growth and the explicit Q4 inventory headwind.

Net read: operationally in line, with a better EPS print offset by softer revenue and no CooperSurgical sale. The filing improves capital-return visibility and shows margin discipline, but the market still needs evidence that CooperVision can resume organic growth after the channel cleanup.

What to watch next

Vision Centre grand opening, September 23, 2026

Original filing on SEC EDGAR

CooperCompanies beats EPS but misses revenue; keeps CooperSurgical, expands buyback | COO Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.